Madrigal Pharmaceuticals (MDGL) Interest Coverage Ratio (2016 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Interest Coverage Ratio of 7.09 for Q2 2026, up 50.42% year-over-year from 4.71 in Q2 2025, and up 40.2% quarter-over-quarter from 11.86 in Q1 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Interest Coverage Ratio (2016 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Interest Coverage Ratio for 16 consecutive years, with 7.09 the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Coverage Ratio rose 50.42% year-over-year to 7.09; the TTM figure through Jun 2026 stood at 2.22 (up 99.85% YoY), while the FY2025 annual figure was 0.51, up 48.11% from the prior year.
- Interest Coverage Ratio improved to 7.09 in Q2 2026 per MDGL's latest filing, from 11.86 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 6.65 in Q4 2024 and bottomed at 90.09 in Q2 2022.
- Historically, Interest Coverage Ratio has averaged 29.26 across 5 years, with a median of 29.51 in 2023.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio soared 122.54% — and 2025, when it slumped 107.36%.
- Madrigal Pharmaceuticals' Interest Coverage Ratio stood at 50.71 in 2022, then soared by 41.81% to 29.51 in 2023, then jumped by 122.54% to 6.65 in 2024, then slumped by 107.36% to 0.49 in 2025, then plunged by 1349.36% to 7.09 in 2026.
- Business Quant data shows MDGL's Interest Coverage Ratio at 7.09 in Q2 2026, 11.86 in Q1 2026, and 0.49 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 14.96 Bn | - | -7.09 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.09 |
| Mar 31, 2026 | -11.86 |
| Dec 31, 2025 | -7.18 |
| Sep 30, 2025 | -15.30 |
| Jun 30, 2025 | -14.30 |
| Mar 31, 2025 | -24.03 |
| Dec 31, 2024 | -19.15 |
| Sep 30, 2024 | -31.61 |
| Jun 30, 2024 | -44.46 |
| Mar 31, 2024 | -39.61 |
| Dec 31, 2023 | -29.51 |
| Sep 30, 2023 | -28.12 |
| Jun 30, 2023 | -29.80 |
| Mar 31, 2023 | -33.53 |
| Dec 31, 2022 | -50.71 |
| Sep 30, 2022 | -53.54 |
| Jun 30, 2022 | -90.09 |
| Jun 30, 2016 | -11.09 |
| Mar 31, 2016 | -0.76 |